Benefits
DashboardNot registered yet? Get a free account.
Sign UpNot registered yet? Get a free account.
Sign Up
You're about to leave our website and go to an external link. Are you sure?
The company contract research and manufacturing company. It provides integrated drug discovery and development services
Syngene International Limited, is an unlisted public company incorporated on 18 November, 1993. It is classified as a public limited company and is located in Bangalore, Karnataka. It's authorized share capital is INR 500.00 cr and the total paid-up capital is INR 402.54 cr.
Read more
Buy Dashboard using Credits
This action will use 1 of your credits. Are you sure you want to go ahead?
Credits Balance:
0
** All rupee values in INR crores. Based on March 2024 numbers.
0.3%
-5.95%
-1.37%
15.82%
-75.37%
-0.24%
-1.02
-1.83
-0.31
-1.94
-2.74
-0.13
Buy Report or Plans
Company dashboard
Five year financials and ratios
Risk analysis
Interactive charts
All financials
All annual returns
MoA and AoA
Latest financials
Latest annual return
MoA and AoA
Five year financials and ratios
Shareholding and group structure
Litigation and more
Everything in financial report
Peers and financials
* GST not included
** Reports & MCA filings will be based on the latest available financials.
India
(11)
| State | Type | Address |
|---|
Locations on Map
Filter (4)
Severe Risk
Moderate Risk
Low Risk
Read more
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Gross margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Networth | |||||
| Borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Debt to equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ROE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| WC days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Equity Capital | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Reserves | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Borrowings + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Long term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Short term borrowings | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade payables + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other liabilities + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total liabilities | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| CWIP | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Intangible assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| LT loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other non-current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Current assets + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Inventories | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Trade receivables | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cash and cash equivalents | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| ST loans and advances | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other current assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Sales + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Sales growth % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Expenses + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Cost of goods | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Employee cost | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other costs | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating profit + | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Other income | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Depreciation | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Exceptional items | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit before tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Tax | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Profit - disc. ops | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net profit | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net margin % | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Solvency + | |||||
| Total Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Debt/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Debt/Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Assets/Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Liquidity + | |||||
| Current Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Quick Ratio | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Interest Coverage | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Performance | |||||
| Gross Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Operating Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Net Margin | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return + | |||||
| Return on Equity | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROCE | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Return on Assets | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Pre-tax ROIC | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Efficiency + | |||||
| Days Payable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Inventory | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Days Receivable | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Fixed Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Total Asset Turnover | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital | |||||
| Cash Conversion Cycle | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
| Working Capital Days | GET PRO | GET PRO | GET PRO | GET PRO | GET PRO |
Kotak Mahindra Bank Limited
No. of Loans: 1
Total Amount : 375.0 cr
| Designation | Name | DIN/PAN | Tenure |
|---|---|---|---|
| Director | Vinita Bali | 00032940 | 7 years |
| Director | Kiran Mazumdar Shaw
Shareholder
|
00347229 | 31 years |
| Director | Nilanjan Roy | 02703775 | 1 years |
| Director | Sharmila Abhay Karve | 05018751 | 5 years |
| Director | Catherine Patricia Rosenberg | 06422834 | 24 years |
| CFO | Sibaji Biswas
Shareholder
|
<HIDDEN> | 5 years |
| Director | Sibaji Biswas | 06959449 | 1 years |
| Director | Vijay Kumar Kuchroo
Shareholder
|
07071727 | 8 years |
| CS | Priyadarshini Mahapatra
Shareholder
|
<HIDDEN> | 5 years |
| CEO | Jonathan Brittan Hunt | <HIDDEN> | 9 years |
| Managing Director | Jonathan Brittan Hunt
Shareholder
|
07774619 | 8 years |
| Director | Kush M Parmar | 09212020 | 3 years |
| Director | Manja Hermina Elisabeth Maria Boerman | 10655368 | 0 years |
| Name | Status | Paid up Capital | Common Directors | Address |
|---|---|---|---|---|
| BAJAJ AUTO LIMITED. |
Active
|
279.3 Cr | 1 | Maharashtra |
| CLINIGENE INTERNATIONAL LIMITED |
Amalgamated
|
5.0 L | 1 | Karnataka |
| BIOCON BIOPHARMACEUTICALS LIMITED |
Amalgamated
|
17.6 Cr | 1 | Karnataka |
| CSEP RESEARCH FOUNDATION |
Active
|
1.0 L | 1 | Delhi |
| IMMUNEEL THERAPEUTICS PRIVATE LIMITED |
Active
|
4.6 L | 1 | Karnataka |
| NARAYANA VAISHNO DEVI SPECIALTY HOSPITALS PRIVATE LIMITED |
Active
|
1.0 Cr | 1 | Karnataka |
| BIOCON RESEARCH LIMITED |
Active
|
5.0 L | 1 | Karnataka |
| BIOCON BIOSPHERE LIMITED |
Active
|
288.6 Cr | 1 | Karnataka |
| SCIENCE GALLERY BENGALURU |
Active
|
0.0 | 1 | Karnataka |
| BIOFUSION THERAPEUTICS LIMITED |
Active
|
5.0 L | 1 | Karnataka |
| GLENLOCH PROPERTIES LLP |
Active
|
1.0 L | 1 | Karnataka |
| MAZUMDAR SHAW MEDICAL FOUNDATION |
Active
|
1.0 L | 1 | Karnataka |
| NARAYANA HRUDAYALAYA LIMITED |
Active
|
204.4 Cr | 1 | Karnataka |
| BIOCON BIOLOGICS LIMITED |
Active
|
1,758.3 Cr | 1 | Karnataka |
| BIOCON LIMITED |
Active
|
600.3 Cr | 1 | Karnataka |
| BIOCON PHARMA LIMITED |
Active
|
887.1 Cr | 1 | Karnataka |
| BIOCON ACADEMY |
Active
|
5.0 L | 1 | Karnataka |
| TRENT LIMITED |
Active
|
35.5 Cr | 1 | Maharashtra |
| AUGERE WIRELESS BROADBAND INDIA PRIVATE LIMITED |
Amalgamated
|
142.3 Cr | 1 | Delhi |
| CSB BANK LIMITED |
Active
|
173.5 Cr | 1 | Kerala |
| AADHAR HOUSING FINANCE LIMITED |
Active
|
426.5 Cr | 1 | Karnataka |
| VANAZ ENGINEERS LIMITED |
Active
|
2.0 Cr | 1 | Maharashtra |
| THOMAS COOK (INDIA) LIMITED |
Active
|
47.0 Cr | 1 | Maharashtra |
| EPL LIMITED |
Active
|
63.7 Cr | 1 | Maharashtra |
| VODAFONE CELLULAR LIMITED |
Amalgamated
|
1,462.6 Cr | 1 | Tamil Nadu |
| VODAFONE SPACETEL LIMITED |
Amalgamated
|
1,025.5 Cr | 1 | Delhi |
| VODAFONE DIGILINK LIMITED |
Amalgamated
|
120.4 Cr | 1 | Delhi |
| SYNGENE SCIENTIFIC SOLUTIONS LIMITED |
Active
|
399.0 Cr | 1 | Karnataka |
| SYNGENE MANUFACTURING SOLUTIONS LIMITED |
Active
|
1.0 Cr | 1 | Karnataka |
| Name | State / Country | Incorporation Year | Paidup Capital |
|---|---|---|---|
| Syngene USA Inc. | United States | - | - |
| SYNGENE SCIENTIFIC SOLUTIONS LIMITED | Karnataka | 2022 | ₹ 399.0 Cr |
| SYNGENE MANUFACTURING SOLUTIONS LIMITED | Karnataka | 2022 | ₹ 1.0 Cr |
The incorporation date of SYNGENE INTERNATIONAL LIMITED is 18 November, 1993
The authorized share capital of SYNGENE INTERNATIONAL LIMITED is INR ₹ 500.0 Cr.
The paid-up capital of SYNGENE INTERNATIONAL LIMITED is INR ₹ 402.5 Cr.
The registered address of SYNGENE INTERNATIONAL LIMITED is Biocon SEZ, Biocon Park,Plot.No.2 & 3, Bommasandra Indst. Area IV Phase, Jigani Link Rd, Bo mmasandra NA Bangalore Karnataka - 560099
The CIN number of SYNGENE INTERNATIONAL LIMITED is L85110KA1993PLC014937.
Expand
Delete
Collapse
See
details
It will take sometime. Please come back in 10
minutes
